No abstract

Rational self-assembly of hexaniobate Lindqvist-type precursor [HNb6O19]7- with soluble Cu2+ salts utilizing different strategies produces a series of giant polyniobate clusters, namely, (H2en)1.25[Cu(en)2(H2O)]2Cl4[Nb24O72H21.5]7 H2O (1; en: ethylenediamine), [Cu(en)2]3[Cu(en)2(H2O)]9[{H2Nb6O19} subset{[({KNb24O72H10.25}{Cu(en)2})2{Cu3(en)3(H2O)3}{Na1.5Cu1.5(H2O)8}{Cu(en)2}4]6}]144 H2O (2), K12Na4[H23NaO8Cu24(Nb7O22)8]106 H2O (3), and K16Na12[H9Cu25.5O8(Nb7O22)8] 73.5 H2O (4). Their structures were determined and further characterized by single-crystal X-ray diffraction analysis, IR and Raman spectroscopy, thermogravimetric analysis (TGA), and elemental analysis. Structural analyses reveal that compound 2 comprises a giant capsule anion based on a wheel-shaped cluster encapsulating a Lindqvist diprotonated cluster [H2Nb6O19]6- unit, and forms a honeycomb-like structure with the inclusion of Lindqvist-type anions [H2Nb6O19]6- in the holes, whereas 3 and 4 represent an unprecedented giant cube-shaped framework. All the compounds are built from [Nb7O22]9- fundamental building blocks. Solution Raman spectroscopy studies of 2 and 3 reveal that the solid-state structures of these polyniobate cluster anions disassemble and exist in the form of the [Nb6O19]8- unit in solution. Magnetic susceptibility measurement of 3 shows antiferromagnetic coupling interactions between CuII ions with the spin-canting phenomenon.

FoundationOne®CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-approved companion diagnostic test to identify patients who may benefit from treatment in accordance with the approved therapeutic product labeling for 28 drug therapies. F1CDx utilizes next-generation sequencing (NGS)-based comprehensive genomic profiling (CGP) technology to examine 324 cancer genes in solid tumors. F1CDx reports known and likely pathogenic short variants (SVs), copy number alterations (CNAs), and select rearrangements, as well as complex biomarkers including tumor mutational burden (TMB) and microsatellite instability (MSI), in addition to genomic loss of heterozygosity (gLOH) in ovarian cancer. CGP services can reduce the complexity of biomarker testing, enabling precision medicine to improve treatment decision-making and outcomes for cancer patients, but only if test results are reliable, accurate, and validated clinically and analytically to the highest standard available. The analyses presented herein demonstrate the extensive analytical and clinical validation supporting the F1CDx initial and subsequent FDA approvals to ensure high sensitivity, specificity, and reliability of the data reported. The analytical validation included several in-depth evaluations of F1CDx assay performance including limit of detection (LoD), limit of blank (LoB), precision, and orthogonal concordance for SVs (including base substitutions [SUBs] and insertions/deletions [INDELs]), CNAs (including amplifications and homozygous deletions), genomic rearrangements, and select complex biomarkers. The assay validation of >30,000 test results comprises a considerable and increasing body of evidence that supports the clinical utility of F1CDx to match patients with solid tumors to targeted therapies or immunotherapies based on their tumor’s genomic alterations and biomarkers. F1CDx meets the clinical needs of providers and patients to receive guideline-based biomarker testing, helping them keep pace with a rapidly evolving field of medicine.

No abstract

A series of inorganic–organic hybrid multifunctional crystalline materials constructed using double-tartaric bridging mono-lanthanide substituted phosphotungstates display reversible photochromic, switchable luminescence, and magnetic properties.